BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. (June 2017) - Kim, Y.H.; Prince, H.M.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.L.; Wolter, P.; Bechter, O.; Wang, Y.; Palanca‐Wessels, M.C.; et al.